SciGen — Shareholder Meeting (November 2002)
10 slides from SciGen's shareholder meeting presentation, Nov 21, 2002
Slide 1: Facsimile: SciGen Presentation given at Sonic Healthcare AGM
21-NOW-2he2 16:19 FROM SCIGEN PTY LTD TO 1368380821 Pat IMScIGEN Facsimile To: ASX Announcements Fax: 1300 300 021 From = Mark Compton Date: 21 November 2002 Pages: 10 (Including cover sheet) Re: SciGen Presentation given at Sonic Healthcare AGM SciGen Presentation given at Sonic Healthcare AGM Plea
Slide 2: SciGen Limited Spin-out and ASX Listing: Introduction
21-NOW-2he2 16t19 FROM SCIGEN PTY LTD TO 1368380821 SciGen Limited Spin -out and ASX Listing November 2002 Mark Compton Chief Executive Officer and Managing Director Introduction SciGen Limited is a bio-pharmaceutical company focussed on the Asia Pacific Region. The Company has a portfolio of licens
Slide 3: Capital Structure and Use of Proceeds
21-NOW-2he2 162 FROM SCIGEN PTY LTD TO 1368380821 Capital Structure Pre Spin-out Post Spin-out Sonic Healthcare Limited 74% 12% SciTech Genetics Pte Ltd 26% 26% New Shareholders “ 62% 100% 100% + New shareholders will hold 1 SciGen share for every fegSciGen Sonic share held. SciGen will have 418,965
Slide 4: Geographic Representation and Product Portfolio
21-NOW-2he2 ifiee FROM SCIGEN PTY LTD TO 1368380821 P. ae Geographic Representation * SciGen has business unit representation in the following countries/regions: KocGen Product Portfolio * SciGen’s product portfolio comprises a range of products. Product Application Estimated World Market $US » Sci-
Slide 5: Sci-B-Vac
21-NOW-2he2 ifiee FROM SCIGEN PTY LTD TO 1368380821 PLAS Sci-B-Va * What is Sci-B Vac™ ? Sci-B-Vac™ is a third generation recombinant hepatitis B vaccine * Immunisation and conditions targeted by Sci-B- Vac™ Sci-B-Vac"™ is a vaccination against hepatitis B. Sci-B-Vac could be used together with anti
Slide 6: SciTropin and SciLin
21-NOW-2he2 ifiee FROM SCIGEN PTY LTD TO 1368380821 P. a6 SciTropin * What is SciTropin™ 7 SciTropin™, is identical to natural human growth hormone. * Diseases and conditions targeted by human growth hormone — Turner's syndrome — short stature due to pituitary growth hormone deficiency — short statu
Slide 7: SciFeron and Sci-DaPT-Vac
21-NOW-2he2 ifiee FROM SCIGEN PTY LTD TO 1368380821 SciFeron * What is SciFeron™ ? SciFeron™ is a highly homogenous, methionine-free recombinant human interferon. * Diseases and conditions are targeted by SciFeron™ Interferon is used in treating virological, oncological and haematological diseases;
Slide 8: SciTojet and Timetable for Future Registrations
21-NOW-2he2 18:21 FR OM = SCIGEN PTY LTD TO 1368380821 SciTojet SciTojet™ - Needle Free Delivery of SciTropin™ and SciLin ™ Wen presaert. the indicator buboiy releases a fing stream: of SciTrogin ‘wmeithrout a media: An datenuatie antety swells Boer trae ye contre) af injection The dotoge Welnhiey s
Slide 9: Partners and Board of Directors
21-NOW-2he2 i621 FROM SCIGEN PTY LTD TO 1368380821 P.ag Partners + SciGen’s major business partners are presented below. Partner Country Bio-Technology General (BTG) USA Peprotech Inc USA Shreya Life Sciences India Akzo Nobel The Netherlands Bioton Poland Ranbaxy Laboratories Limited India Antares P
Slide 10: Scientific Advisory Board
21-NOW-2he2 i621 FROM SCIGEN PTY LTD TO 1368380821 P.1a Scientific Advisory Board Profeseer Marian Gorecki Israel Ph.D Professor Chan Soh Ha Singapore MBBS, Ph.D Professor Daniel Shouval Israel MD Dr Yitzhak Stabinsky California Ph.D Professor David J Handelsman Sydney Mg 8S, PH.D, FRAGP (SciGen Sci